Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced Epithelial Ovarian Cancer: Merck Ruchika Sharma11 Dec 2024 5:54 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA...
Imfinzi, Lynparza combo approved in EU for mismatch repair proficient advanced or recurrent endometrial cancer: AstraZeneca Ruchika Sharma18 Aug 2024 10:00 AM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain...
Lynparza, Imfinzi combo recommended for nod in EU by CHMP for endometrial cancer: AstraZeneca Ruchika Sharma3 July 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU)...
CDSCO Panel grants AstraZeneca's proposal for withdrawing specific Indications of Olaparib Tablets Dr. Divya Colin11 April 2024 6:00 PM ISTNew Delhi: Reviewing the Clinical evidence presented by drug major AstraZeneca, the Subject Expert Committee (SEC) functional under the Central Drug...
Dr Reddy’s permanently restrained by Delhi HC from commercially launching any product consisting of 'Olaparib' Roshni Dhar5 Jan 2024 3:46 PM ISTThe Delhi High Court has issued a permanent injunction against Dr. Reddy’s Laboratories Limited, restraining it from commercially launching any...
Health Bulletin 4/January/2024 Roshni Dhar4 Jan 2024 5:13 PM ISTHere are the top health stories for the day:Delhi HC permanently restrains Dr Reddy’s from commercially launching any product consisting of...
Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
AstraZeneca's Lynparza plus abiraterone approved in Japan for treatment of BRCA-mutated metastatic castration-resistant prostate cancer Ruchika Sharma26 Aug 2023 11:30 AM ISTCambridge: AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of...
AstraZeneca announces positive results from ovarian cancer combo therapy trial Ruchika Sharma7 April 2023 11:30 AM ISTThe safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the...
Conduct Phase III CT : CDSCO panel tells AstraZeneca for anticancer drug Olaparib Film coated Tablet Dr. Divya Colin17 March 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the drug major...
Medical Bulletin 28/October/2022 Isra Zaman28 Oct 2022 5:00 PM ISTHere are the top medical news for the day:Specific alterations in the BRAF gene found that may affect treatment and survival response in adult brain...
Olaparib and adavosertib, work best when given sequentially in patients with advanced tumours: results from Phase Ib STAR clinical trial Isra Zaman28 Oct 2022 10:00 AM ISTPresenting results from the phase Ib STAR clinical trial to the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in...
